Business Wire

HIBER

2.11.2020 09:02:06 CET | Business Wire | Press release

Share
World’s First End-to-End IoT Subscription Service for Remote Monitoring Launched by Hiber With Oil & Gas Well Integrity Monitoring to Prevent Leakage & Build a More Sustainable Practice

Dutch satellite Internet-of-Things (IoT) solution startup, Hiber , today announces the launch of HiberHilo , its first end-to-end solution for Oil & Gas Well Integrity Monitoring. HiberHilo is also the world’s first subscription service for IoT-enabled remote Oil/Gas Well monitoring and the company will be introducing similar services for other specific use cases in 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005336/en/

There is a growing demand for remote monitoring in industries such as Oil & Gas to create more sustainable and environmentally friendly practices, especially with COVID-19 limiting travel halting routine maintenance checks. However, the IoT SaaS market in this space is nascent and lacks simplicity. Having already been one of the first firms to develop a remote IoT connectivity solution with the launch of its proprietary nano-satellites in 2018, Hiber identified the urgent need for readily available out-the-box end-to-end subscription based offerings. These must be designed bespoke for particular use cases, as well as being simple and efficient for businesses to install and implement.

The HiberHilo solution for Oil & Gas Well Integrity Monitoring is the first offering of this kind that Hiber will launch because this process is currently complex, time-consuming and expensive (costing up to $40,000 per field visit). Additionally, manual monitoring is prone to error and is often not conducted frequently enough.

Monitoring is critical to ensure that anomalies are identified early and addressed - this can include potential leaks which, if left unaddressed, can impact people’s health and safety as well as negatively impact the environment. HiberHilo’s out-of-the-box subscription solution utilises Hiber’s global satellite network to empower organisations to automate continuous annulus pressure and wellhead monitoring of up to 250 wells in a radius of 10km, even in the most remote locations on Earth. Pricing starts at $449 per month per well (1 sensor and a 5 year contract).

The all-in-one product is available as both a starter kit and in the form of an enterprise solution, both of which feature:

  • A pressure and optional temperature sensor to ensure accurate and regular measurements - organisations can add more sensors to the network if required
  • Easy connectivity anywhere, sending up to 24 messages a day or one per hour
  • Alarm and alert settings
  • An intuitive dashboard for desktop and mobile
  • Support both on-site and via mobile

Coen Janssen, co-founder and Chief Strategy Officer at Hiber said , “We are excited to launch this first-of-its-kind IoT proposition for remote monitoring at a time when it is needed more than ever. HiberHilo has already been proven by Nederlandse Aardolie Maatschappij (NAM) and Royal Dutch Shell (better known as just “Shell”) on an abandoned on-shore well. This technology can be installed in less than 2 hours and within 0.25% accuracy levels of a traditional wired system, which is extremely reliable.”

“We look forward to more companies embracing this new proposition as it will save them time, money and lives by allowing teams to monitor well integrity from home as well as reducing the risk of well integrity issues to create more sustainable practices. The future for remote monitoring is very bright!”

Hiber entered the market in 2018 purely as a connectivity provider, utilising its own proprietary nano-satellite technology to unlock IoT connectivity in the 90% of the world without it. For more information on HiberHilo visit: hiberhilo.com or watch this video .

-- ENDS --

About Hiber

Hiber is an Internet of Things (IoT) solution startup, founded and led by a dream team of satellite experts and tech entrepreneurs. These 'Hibernauts' are working on a moonshoot goal: to launch and provide end-to-end IoT solutions connected by satellites in space. More than 55 employees work on the ground-breaking technology behind Hiber and Hiberband at its offices in the Netherlands and USA.

To date, the company has managed to attract significant funding. This has meant that in November 2018 Hiber became the Netherlands’ first commercial satellite company, launching its first two nano-satellites into orbit. Hiber officially launched at the Amazon Web Services’ (AWS) Re:invent Conference in November 2018 where they were named Commercial Startup Launch of 2018 at the AWS conference.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye